Testimony of Dr. José Navarro on behalf of quadraScope Ventures

Thank you for the opportunity to provide testimony on HB 1292-FN. My name is José Navarro. I am a physician-scientist with an MD and a PhD, and I serve as the Scientific Director of quadraScope Ventures, a venture capital fund based in the Boston area. We invest in early-stage healthcare companies that enable disease treatment and prevention through the reversal of biological age.

I have had the opportunity to work in healthcare from three distinct angles: in the clinic, in the lab, and on the investment side. From these experiences, I have become very passionate about translational medicine. In short, translational medicine bridges the gap between a discovery in basic science and its application in patients.

HB 1292 accelerates translational medicine by creating a safe ecosystem in which accredited facilities and licensed physicians can provide patients with access to life-changing therapies under strict oversight. I urge the committee to give this bill a favorable recommendation. Let me briefly explain why.

For an investor, seeing a therapy used safely and demonstrating early markers of efficacy, even in a small number of patients, is enormously informative. For the companies developing those therapies, it means the opportunity to validate their research on a shorter timeline than traditional randomized controlled trials would permit.

Beyond the benefits to individual companies, there is a broader competitiveness issue at stake. Asian healthcare companies currently benefit from regulatory systems that allow them to generate clinical data faster and at a lower cost. These companies come to the table with early clinical data that is highly attractive to big pharma. In the first three quarters of 2025 alone, Chinese companies signed out-licensing deals totaling nearly $70B[1]. By leveraging its proximity to Boston's research hub and talent pool, New Hampshire has a unique opportunity to attract talent in the region and help domestic companies generate the early clinical evidence they need to compete.

By creating a legislative environment friendly to translational medicine, New Hampshire stands to secure three wins. First, patients gain access to life-changing therapies years ahead of the FDA timeline. Second, scientists and investors gain real-world evidence on breakthrough treatments. Finally, the state gains a powerful economic engine. Our firm, along with other investors, would be inclined to invest in New Hampshire–based companies that benefit from an innovation-friendly legislative environment.

1 - L.E.K. Consulting, *Advancing Innovation and Global Reach: The Next Chapter in China's Clinical Trial Development* (2025).